Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Piccart

Showing results (51-60 of 186) with videos related to

Pageof 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
A phase I trial of a new antiemetic drug--clebopride malate--in cisplatin-treated patientsH Bleiberg, M Piccart, S Lips, et al.
Scandinavian Journal of Infectious Diseases. Supplementum|January 1, 1990
Therapy of infections related to intraperitoneal catheters in patients with ovarian cancerF Meunier, P van der Auwera, M Aoun, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
N-(Phosphonacetyl)-L-aspartate (PALA): current statusM Rozencweig, R Abele, M Piccart, et al.
Oncogene|June 30, 2015
Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designsZ Fadoukhair, D Zardavas, M A Chad, et al.
Breast (Edinburgh, Scotland)|August 25, 2004
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activationM S Mano, A Awada, A Minisini, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, L Mauriac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2018
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysisY Bareche, D Venet, M Ignatiadis, et al.
Breast Cancer Research and Treatment|January 1, 1996
Tamoxifen aziridine labeling of the estrogen receptor-potential utility in detecting biologically aggressive breast tumorsS Trivedi, M Piccart, C Muquardt, et al.
Breast Cancer Research and Treatment|January 5, 2002
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, T Cufer, et al.
Revue Medicale De Bruxelles|March 1, 1983
[Preliminary study of a combination of fluorouracil and cisplatin in the treatment of tumors of the colon]B Vanderlinden, M Rozencweig, M Piccart, et al.
Pageof 19

Showing results (51-60 of 186) with videos related to

Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1992
A phase I trial of a new antiemetic drug--clebopride malate--in cisplatin-treated patientsH Bleiberg, M Piccart, S Lips, et al.
Scandinavian Journal of Infectious Diseases. Supplementum|January 1, 1990
Therapy of infections related to intraperitoneal catheters in patients with ovarian cancerF Meunier, P van der Auwera, M Aoun, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1980
N-(Phosphonacetyl)-L-aspartate (PALA): current statusM Rozencweig, R Abele, M Piccart, et al.
Oncogene|June 30, 2015
Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designsZ Fadoukhair, D Zardavas, M A Chad, et al.
Breast (Edinburgh, Scotland)|August 25, 2004
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activationM S Mano, A Awada, A Minisini, et al.
European Journal of Cancer (Oxford, England : 1990)|May 24, 2003
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, L Mauriac, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 25, 2018
Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysisY Bareche, D Venet, M Ignatiadis, et al.
Breast Cancer Research and Treatment|January 1, 1996
Tamoxifen aziridine labeling of the estrogen receptor-potential utility in detecting biologically aggressive breast tumorsS Trivedi, M Piccart, C Muquardt, et al.
Breast Cancer Research and Treatment|January 5, 2002
An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancerH Bonnefoi, L Biganzoli, T Cufer, et al.
Revue Medicale De Bruxelles|March 1, 1983
[Preliminary study of a combination of fluorouracil and cisplatin in the treatment of tumors of the colon]B Vanderlinden, M Rozencweig, M Piccart, et al.
Pageof 19